Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Lonza Sanquin Reagents have entered into a strategic partnership for the commercialization of a range of specialized reagents for pyrogen testing of parenteral pharmaceuticals and medical devices using the Monocyte Activation Test.
read more
Wednesday, January 19, 2022
Forbion, BioGeneration Ventures and Lonza announced the extension of their collaboration to include the development and manufacturing of small molecules.
read more
Wednesday, April 03, 2019
Chr. Hansen Holding A/S and Lonza have signed an agreement to establish a 50/50 joint venture to develop the live biotherapeutic products (LBPs) industry.
read more
Lonza and CELLINK have partnered to offer a 3D bioprinting solution designed to optimize and increase access to complete 3D cell culture workflows.
read more
Wednesday, March 08, 2023
Lonza announced an enhancement to its powder characterization capabilities at its Small Molecules site in Tampa, Florida (US).
read more
Lonza announced the addition of clinical bottling and labeling capabilities at its Small Molecules site in Bend, Oregon (US). Building upon the recent investment in the dedicated early-phase clinical manufacturing facility, the offering now includes ...
read more
Lonza now offers a comprehensive portfolio of fresh and cryopreserved human and animal hepatocytes for ADME-Tox testing, further strengthening its position as a leader in cell discovery.
read more
Wednesday, December 13, 2023
Medivir AB announced that it has signed an agreement with Lonza for the manufacture of a new GMP campaign of fostrox drug substance for the planned phase 2b to enable study drug availability end of 2024 and ensure maximum momentum in the fostrox ...
read more
Lonza announced it will invest in additional inhalation capabilities. The investment will fund the build-out of an additional inhalation testing capacity at the Tampa (US) site specialized in development, clinical, and commercial manufacturing of ...
read more
Lonza announced an investment in a major expansion of Highly Potent API (HPAPI) capacity at its Visp, CH site.
read more
Thursday, November 06, 2025
Lonza announced that it has signed an agreement to acquire Redberry SAS (Redberry), an innovative company specializing in rapid microbiology testing solutions using solid-phase cytometry (SPC) technology.
read more
Tuesday, November 12, 2024
Lonza announced it will invest in additional bioconjugation capabilities in Visp (CH). The expansion will add two multipurpose 1,200L manufacturing suites and manufacturing-related infrastructure to the?existing bioconjugation facility in Visp (CH) ...
read more
Monday, December 10, 2018
Lonza announced an agreement with GE Healthcare under which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou.
read more
Lonza has entered into a definitive agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3 billion (USD 3 billion). Lonza will realize upfront cash proceeds of CHF 1.7 billion (USD 2...
read more
Following the recent FDA approval of the PAS for second-generation Andexxa, Portola and Lonza announce the start of supply of the recombinant coagulation factor from Lonza’s Porriño facility.
read more